Encephalitis Virus (JEV/SLEV/TBEV) Research Reagents — Antibodies & Recombinant Proteins

Encephalitis viruses including Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV), and tick-borne encephalitis virus (TBEV) are flaviviruses causing severe neuroinflammatory disease with significant mortality and morbidity in endemic regions. These viruses have a positive-sense single-stranded RNA genome encoding three structural proteins—the capsid (C) protein, premembrane (PrM) protein, and envelope (E) protein—and seven non-structural proteins (NS1-NS5). The E protein is the primary target for neutralizing antibodies and vaccine development; NS1 is an important diagnostic marker and immune antagonist. Research reagents are essential for diagnostic assay development, vaccine immunogenicity studies, and mechanistic understanding of viral pathogenesis.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Encephalitis virus structure — E protein, PrM, and capsid

Fig. 1 Encephalitis virus structure. E protein mediates receptor binding and cell entry; PrM protein aids virion assembly; capsid protein encapsidates the genome. NS proteins drive replication and immune modulation.

abinScience provides monoclonal and polyclonal detection antibodies, recombinant antigens, and ELISA kits for JEV, SLEV, and TBEV research. All products manufactured by our parent company AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems. Contact us for vaccine development and diagnostic assay optimization.

Key Research Targets

Envelope Protein (E) — E protein is the primary surface antigen mediating receptor binding and cell entry, and is the major target for neutralizing antibodies. E-specific neutralizing antibodies provide the strongest protective immunity and form the foundation of vaccine development. Anti-E polyclonal and monoclonal antibodies (VK731014, VK731034, VK731013) support neutralization assays, ELISA-based serodiagnosis, and epitope mapping studies. E protein serves as the principal ELISA coating antigen and vaccine immunogen candidate for JEV, SLEV, and TBEV research.
→ Browse Encephalitis E protein products

Premembrane/Membrane (PrM/M) Protein & Capsid (C) Protein — PrM protein aids virion maturation and assembly; the capsid protein encapsidates the viral genome. Both proteins are immunogenic and contribute to overall vaccine-induced protection. Anti-PrM and anti-C antibodies (VK748014, VK638014) support diagnostic assay development, viral antigen detection, and characterization of the complete humoral immune response. Recombinant PrM and C proteins serve as ELISA coating antigens and immunogenicity assessment standards.
→ Browse Encephalitis structural protein products

Non-Structural Proteins (NS1, NS3, NS5) — NS1 is secreted during infection and serves as an important diagnostic marker and immune antagonist. NS3 is a serine protease essential for polyprotein processing; NS5 is the RNA-dependent RNA polymerase. NS-specific antibodies (VK489014, VK793014, VK693014, VK786014) enable detection of active viral replication, diagnostic serodiagnosis, and mechanistic studies of viral polyprotein processing. NS1 is particularly useful as a biomarker for acute infection and as a diagnostic antigen distinct from structural proteins.
→ Browse all Encephalitis virus products

Recommended Applications

Serological Diagnosis & Seroprevalence Studies
E protein and NS1 recombinant antigens are optimal ELISA coating antigens for rapid IgM and IgG serodetection in acute and convalescent encephalitis cases. Monoclonal and polyclonal antibody pairs enable sandwich ELISA development for high-sensitivity, high-specificity diagnostic assays. NS1-specific detection distinguishes active from past infection in epidemiological surveys and outbreak investigations.

Vaccine Development & Immunogenicity Assessment
E protein-specific neutralizing antibodies quantify vaccine-induced protection in vaccinated populations. NS-specific antibody responses characterize the breadth of the immune response and support vaccine strain selection. Recombinant E, PrM, and NS proteins serve as immunogens, coating antigens, and potency testing standards for JEV, SLEV, and TBEV vaccine development programs.

References

1. Campbell GL, Hills SL, Fischer M, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766-774E.

2. Pierson TC, Diamond MS. The continued threat of emerging flaviviruses. Nat Microbiol. 2020;5(6):796-812.

3. Heinz FX, Stiasny K. Flaviviruses and their antigenic structure. J Clin Virol. 2012;55(4):289-295.

4. Bardina SV, Chambers TJ, Vogel SN, Morrison J, Pletnev AG. Neurovirulence of tick-borne encephalitis virus is determined by properties of the viral polymerase rather than structural proteins. J Virol. 2017;91(6):e02502-16.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems. Contact us for custom antibody development.